Synergetic effect of poly (ADP-ribosyl) polymerase (PARP) inhibitor and cisplatin on ovarian cancer

Yanyi Li, Ying Shan, Yingchun Duan, Jiang Cui, A Jisaihan, Yuko OhnoTropical 2022 · DOI

Abstract

Purpose: To investigate the effect of the combination of poly (ADP-ribosyl) polymerase (PARP) inhibitor, talazoparib (BMN673), and cisplatin on the proliferation and apoptosis of ovarian cancer cells in vitro, and on xenograft tumors of ovarian cancer cells in vivo.
Methods: Cell viability was determined by CCK-8 assay, while cell proliferation and cell cycle were assessed using colony formation assay and flow cytometry, respectively. Cell apoptosis was evaluated by flow cytometry and TUNEL assays. Western blot assay was used to measure the expression levels of proliferation- and apoptosis-related proteins.
Results: The PARP inhibitor, BMN673, produced a dose-dependent synergistic effect with cisplatin (p < 0.05). Compared with when cisplatin or BMN673 was used alone, the combination of cisplatin and BMN673 significantly inhibited the growth of transplanted tumors (p < 0.05). Immunohistochemical analysis showed that cisplatin and BMN673 treatment increased the number of cells positive for TUNEL, but reduced the population of cells positive for Ki67.
Conclusion: Thus, BMN673 and cisplatin are synergistic against ovarian cancer cells, and therefore, should be subjected to further investigations, including clinical trials, to determine the potentials of the combination for the management of ovarian carcinoma.

Introduction

Ovarian cancer remains the most lethal gynecological malignancy, primarily due to late-stage diagnosis and the eventual development of resistance to standard platinum-based chemotherapies such as cisplatin. PARP inhibitors have emerged as a revolutionary class of drugs that exploit defects in DNA repair pathways. Talazoparib (BMN673) is a highly potent PARP1/2 inhibitor, significantly more effective at lower concentrations than earlier generation inhibitors. This study explores the potential of combining BMN673 with cisplatin to overcome chemoresistance and enhance therapeutic efficacy in ovarian cancer models.

Methods

The research utilized human ovarian carcinoma cell lines SKOV-3 and OVCAR-3. In vitro assessments included CCK-8 and colony formation assays for cell viability and proliferation, and flow cytometry for cell cycle and apoptosis analysis. Protein expression of markers such as PCNA, Ki67, Caspase-3, Bax, and Bcl-2 was quantified via Western blotting. For in vivo validation, a xenograft model was established using BALB/C nude mice, where tumor growth was monitored under treatment with saline, cisplatin, BMN673, or the combination.

Results

Single-Agent Dose Response

Initial experiments established the baseline sensitivity of SKOV-3 and OVCAR-3 cells to BMN673 and cisplatin. Both agents demonstrated significant, dose-dependent inhibition of cell proliferation across both cell lines. BMN673 showed high potency in the nanomolar range, while cisplatin (DDP) showed efficacy in the microgram range.

Dose-dependent inhibition of SKOV-3 and OVCAR-3 cell proliferation by BMN673 (A) and Cisplatin (B).

Synergistic Effects and Mechanism

The combination of 10 nM BMN673 and 5 μg/mL cisplatin produced a synergistic cytotoxic effect significantly greater than either drug alone ($p < 0.05$). Mechanistically, the combination treatment induced cell cycle arrest at the G0/G1 phase and promoted apoptosis. This was confirmed by Western blot analysis showing an increase in pro-apoptotic Bax and Caspase-3 levels, alongside a decrease in anti-apoptotic Bcl-2.

In Vivo Tumor Suppression

In the mouse xenograft model, the combination therapy resulted in significantly smaller tumor volumes and weights compared to the control and monotherapy groups. Immunohistochemical staining of the excised tumors revealed a marked increase in TUNEL-positive cells (indicating DNA fragmentation) and a decrease in Ki67-positive cells (indicating reduced active proliferation), validating the in vitro findings.

Discussion and Conclusion

The synergistic interaction between BMN673 and cisplatin likely stems from a "double hit" to the cancer cell's DNA. Cisplatin induces DNA cross-links, while BMN673 inhibits the PARP-mediated repair of these lesions, leading to lethal genomic instability. This combination not only enhances the efficacy of cisplatin but may also help circumvent the mechanisms of platinum resistance. These results provide a strong rationale for further clinical investigation into this combination therapy as a potential management strategy for advanced or resistant ovarian carcinoma.

Summary updated

Abstract

Purpose: To investigate the effect of the combination of poly (ADP-ribosyl) polymerase (PARP) inhibitor, talazoparib (BMN673), and cisplatin on the proliferation and apoptosis of ovarian cancer cells in vitro, and on xenograft tumors of ovarian cancer cells in vivo.&#x0D; Methods: Cell viability was determined by CCK-8 assay, while cell proliferation and cell cycle were assessed using colony formation assay and flow cytometry, respectively. Cell apoptosis was evaluated by flow cytometry and TUNEL assays. Western blot assay was used to measure the expression levels of proliferation- and apoptosis-related proteins.&#x0D; Results: The PARP inhibitor, BMN673, produced a dose-dependent synergistic effect with cisplatin (p &lt; 0.05). Compared with when cisplatin or BMN673 was used alone, the combination of cisplatin and BMN673 significantly inhibited the growth of transplanted tumors (p &lt; 0.05). Immunohistochemical analysis showed that cisplatin and BMN673 treatment increased the number of cells positive for TUNEL, but reduced the population of cells positive for Ki67.&#x0D; Conclusion: Thus, BMN673 and cisplatin are synergistic against ovarian cancer cells, and therefore, should be subjected to further investigations, including clinical trials, to determine the potentials of the combination for the management of ovarian carcinoma.&#x0D; Keywords: PARP inhibitor; Ovarian cancer; Xenografted tumor; Cisplatin
BibTeX
@inproceedings{li2022synergetic,
  author = {Yanyi Li and Ying Shan and Yingchun Duan and Jiang Cui and A Jisaihan and Yuko Ohno},
  title = {{Synergetic effect of poly (ADP-ribosyl) polymerase (PARP) inhibitor and cisplatin on ovarian cancer}},
  booktitle = {Tropical},
  year = {2022},
  doi = {10.4314/tjpr.v21i7.7},
}
Figure